Evolving Treatments for Acute Ischemic Stroke

Circulation Research

Volumn 118, Issue 9, 2016, Pages 1425-1442

  Zerna, Charlotte ^a   Hegedus, Janka ^a   Hill, Michael D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

biomarker; secondary prevention; standard of care; stroke; thrombectomy thrombolysis

Indexed keywords

BIOLOGICAL MARKER; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; FIBRINOLYTIC AGENT;

ATRIAL FIBRILLATION; BARTHEL INDEX; BLOOD CLOT LYSIS; BRAIN BLOOD FLOW; BRAIN CIRCULATION; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HEALTH CARE QUALITY; HUMAN; IMAGING; LACUNAR STROKE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERCUTANEOUS THROMBECTOMY; PRIORITY JOURNAL; RANKIN SCALE; RECURRENT DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; THROMBECTOMY DEVICE; CLASSIFICATION; DIAGNOSTIC IMAGING; STROKE;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; STROKE;

EID: 84968542459     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.307005     Document Type: Review

References (154)

1. Biller J. Vascular diseases of the nervous system. In: R. Daroff, ed. Bradley's Neurology in Clinical Practice. 6th ed. Elsevier Inc; 2012: 1003-1053.e5.
2. Auer RN. Histopathology of cerebral ischemia. In: J. P. Mohr, ed. Stroke Pathophysiology Diagnosis and Management. 5th ed. Saunders; 2011: 68-74.
3. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, Sherman DG; TIA Working Group. Transient ischemic attack-proposal for a new definition. N Engl J Med. 2002;347:1713-1716. doi: 10.1056/NEJMsb020987.
4. Khatri P. Evaluation and management of acute ischemic stroke. Continuum (Minneap Minn). 2014;20:283-295. doi: 10.1212/01. CON.0000446101.44302.47.
5. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254.
6. Good DC, Bettermann K, Reichwein RK. Stroke rehabilitation. Continuum (Minneap Minn). 2011;17:545-567. doi: 10.1212/01.CON. 0000399072.61943.38.
7. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000;355:1670-1674.
8. Puetz V, Dzialowski I, Hill MD, Demchuk AM. The Alberta Stroke Program Early CT Score in clinical practice: what have we learned? Int J Stroke. 2009;4:354-364. doi: 10.1111/j.1747-4949.2009.00337.x.
9. Gupta AC, Schaefer PW, Chaudhry ZA, Leslie-Mazwi TM, Chandra RV, González RG, Hirsch JA, Yoo AJ. Interobserver reliability of baseline noncontrast CT Alberta Stroke Program Early CT Score for intra-arterial stroke treatment selection. AJNR Am J Neuroradiol. 2012;33:1046-1049. doi: 10.3174/ajnr.A2942.
10. Barber PA, Hill MD, Eliasziw M, Demchuk AM, Pexman JH, Hudon ME, Tomanek A, Frayne R, Buchan AM; ASPECTS Study Group. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry. 2005;76:1528-1533. doi: 10.1136/jnnp.2004.059261.
11. Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk AM, Hill MD, Patronas N, Latour L, Warach S. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet. 2007;369:293-298. doi: 10.1016/S0140-6736(07)60151-2.
12. Dzialowski I, Hill MD, Coutts SB, Demchuk AM, Kent DM, Wunderlich O, von Kummer R. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke. 2006;37:973-978. doi: 10.1161/01.STR.0000206215.62441.56.
13. Hill MD, Demchuk AM, Goyal M, Jovin TG, Foster LD, Tomsick TA, von Kummer R, Yeatts SD, Palesch YY, Broderick JP; IMS3 Investigators. Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014;45:444-449. doi: 10.1161/STROKEAHA.113.003580.
14. Haussen DC, Lima A, Frankel M, Anderson A, Belagaje S, Nahab F, Rangaraju S, Nogueira RG. Sulcal effacement with preserved gray-white junction: a sign of reversible ischemia. Stroke. 2015;46:1704-1706. doi: 10.1161/STROKEAHA.115.009304.
15. Arba F, Palumbo V, Boulanger JM, Pracucci G, Inzitari D, Buchan AM, Hill MD; CASES Investigators. Leukoaraiosis and lacunes are associated with poor clinical outcomes in ischemic stroke patients treated with intravenous thrombolysis. Int J Stroke. 2016;11:62-67. doi: 10.1177/1747493015607517.
16. Berkhemer OA, van Zwam WH, Dippel DW; MR CLEAN Investigators. Stent-Retriever Thrombectomy for Stroke. N Engl J Med. 2015;373:1076. doi: 10.1056/NEJMc1508744#SA1.
17. Goyal M, Demchuk AM, Menon BK, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019-1030. doi: 10.1056/NEJMoa1414905.
18. Campbell BC, Mitchell PJ, Kleinig TJ, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009-1018. doi: 10.1056/NEJMoa1414792.
19. Saver JL, Goyal M, Diener HC; SWIFT PRIME Investigators. Stent-Retriever Thrombectomy for Stroke. N Engl J Med. 2015;373:1077. doi: 10.1056/NEJMc1508744.
20. Jovin TG, Chamorro A, Cobo E, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296-2306. doi: 10.1056/NEJMoa1503780.
21. Khatri P, Abruzzo T, Yeatts SD, Nichols C, Broderick JP, Tomsick TA; IMS I and II Investigators. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009;73:1066-1072. doi: 10.1212/WNL.0b013e3181b9c847.
22. Menon BK, Smith EE, Modi J, Patel SK, Bhatia R, Watson TW, Hill MD, Demchuk AM, Goyal M. Regional leptomeningeal score on CT angiography predicts clinical and imaging outcomes in patients with acute anterior circulation occlusions. AJNR Am J Neuroradiol. 2011;32:1640-1645. doi: 10.3174/ajnr.A2564.
23. Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, Parsons MW. The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain. 2009;132:2231-2238. doi: 10.1093/brain/awp155.
24. Sheth SA, Sanossian N, Hao Q, Starkman S, Ali LK, Kim D, Gonzalez NR, Tateshima S, Jahan R, Duckwiler GR, Saver JL, Vinuela F, Liebeskind DS; UCLA Collateral Investigators. Collateral flow as causative of good outcomes in endovascular stroke therapy. J Neurointerv Surg. 2016;8:2-7. doi: 10.1136/neurintsurg-2014-011438.
25. Ezzeddine MA, Lev MH, McDonald CT, Rordorf G, Oliveira-Filho J, Aksoy FG, Farkas J, Segal AZ, Schwamm LH, Gonzalez RG, Koroshetz WJ. CT angiography with whole brain perfused blood volume imaging: added clinical value in the assessment of acute stroke. Stroke. 2002;33:959-966.
26. Coutts SB, Lev MH, Eliasziw M, Roccatagliata L, Hill MD, Schwamm LH, Pexman JH, Koroshetz WJ, Hudon ME, Buchan AM, Gonzalez RG, Demchuk AM. ASPECTS on CTA source images versus unenhanced CT: added value in predicting final infarct extent and clinical outcome. Stroke. 2004;35:2472-2476. doi: 10.1161/01.STR.0000145330.14928.2a.
27. Menon BK, d'Esterre CD, Qazi EM, Almekhlafi M, Hahn L, Demchuk AM, Goyal M. Multiphase CT Angiography: A New Tool for the Imaging Triage of Patients with Acute Ischemic Stroke. Radiology. 2015;275:510-520. doi: 10.1148/radiol.15142256.
28. Zerna C, Assis Z, d'Esterre CD, Menon BK, Goyal M. Imaging, Intervention, and Workflow in Acute Ischemic Stroke: The Calgary Approach. AJNR. 2015.
29. Coutts SB, Modi J, Patel SK, Aram H, Demchuk AM, Goyal M, Hill MD. What causes disability after transient ischemic attack and minor stroke?: Results from the CT and MRI in the Triage of TIA and minor Cerebrovascular Events to Identify High Risk Patients (CATCH) Study. Stroke. 2012;43:3018-3022. doi: 10.1161/STROKEAHA.112.665141.
30. Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, Manns BJ, Ghali WA. Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med. 2007;167:2417-2422. doi: 10.1001/archinte.167.22.2417.
31. Coutts SB, Modi J, Patel SK, Demchuk AM, Goyal M, Hill MD; Calgary Stroke Program. CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and minor stroke: results of the prospective CATCH study. Stroke. 2012;43:1013-1017. doi: 10.1161/STROKEAHA.111.637421.
32. Brouwers HB, Battey TW, Musial HH, et al. Rate of contrast extravasation on computed tomographic angiography predicts hematoma expansion and mortality in primary intracerebral hemorrhage. Stroke. 2015;46:2498-2503. doi: 10.1161/STROKEAHA.115.009659.
33. Zussman B. Behind the technology: CT perfusion in the setting of acute ischemic stroke. JHN J. 2010;5.
34. Campbell BC, Yassi N, Ma H, Sharma G, Salinas S, Churilov L, Meretoja A, Parsons MW, Desmond PM, Lansberg MG, Donnan GA, Davis SM. Imaging selection in ischemic stroke: feasibility of automated CTperfusion analysis. Int J Stroke. 2015;10:51-54. doi: 10.1111/ijs.12381.
35. d'Esterre CD, Roversi G, Padroni M, Bernardoni A, Tamborino C, De Vito A, Azzini C, Marcello O, Saletti A, Ceruti S, Lee TY, Fainardi E. CT perfusion cerebral blood volume does not always predict infarct core in acute ischemic stroke. Neurol Sci. 2015;36:1777-1783. doi: 10.1007/s10072-015-2244-8.
36. Birenbaum D, Bancroft LW, Felsberg GJ. Imaging in acute stroke. West J Emerg Med. 2011;12:67-76.
37. Srinivasan A, Goyal M, Al Azri F, Lum C. State-of-the-art imaging of acute stroke. Radiographics. 2006;26(suppl 1):S75-S95. doi: 10.1148/rg.26si065501.
38. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. Jama. 2013;309:2480-2488.
39. Meretoja A, Keshtkaran M, Saver JL, Tatlisumak T, Parsons MW, Kaste M, Davis SM, Donnan GA, Churilov L. Stroke thrombolysis: save a minute, save a day. Stroke. 2014;45:1053-1058. doi: 10.1161/STROKEAHA.113.002910.
40. Goyal M, Fargen KM, Menon BK. Acute stroke, Bayes' theorem and the art and science of emergency decision-making. J Neurointerv Surg. 2014;6:256-259. doi: 10.1136/neurintsurg-2013-011056.
41. Kwakkel G, Kollen BJ. Predicting activities after stroke: what is clinically relevant? Int J Stroke. 2013;8:25-32. doi: 10.1111/j.1747-4949.2012.00967.x.
42. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet. 2011;377:1693-1702. doi: 10.1016/S0140-6736(11)60325-5.
43. Heller A, Wade DT, Wood VA, Sunderland A, Hewer RL, Ward E. Arm function after stroke: measurement and recovery over the first three months. J Neurol Neurosurg Psychiatry. 1987;50:714-719.
44. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke. 1999;30:1538-1541.
45. RANKIN J. Cerebral vascular accidents in patients over the age of 60. III. Diagnosis and treatment. Scott Med J. 1957;2:254-268.
46. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007;38:1091-1096. doi: 10.1161/01. STR.0000258355.23810.c6.
47. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
48. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
49. Uyttenboogaart M, Luijckx GJ, Vroomen PC, Stewart RE, De Keyser J. Measuring disability in stroke: relationship between the modified Rankin scale and the Barthel index. J Neurol. 2007;254:1113-1117. doi: 10.1007/s00415-007-0646-0.
50. Quinn TJ, Langhorne P, Stott DJ. Barthel index for stroke trials: development, properties, and application. Stroke. 2011;42:1146-1151. doi: 10.1161/STROKEAHA.110.598540.
51. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified Rankin Scale: a systematic review. Stroke. 2009;40:3393-3395. doi: 10.1161/STROKEAHA.109.557256.
52. Hobart J. Measuring outcomes in clinical trials of stroke: time for stateof-the-art clinical trials to reject state-of-the-ark rating scales. J Neurol. 2007;254:1119. doi: 10.1007/s00415-007-0535-6.
53. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055-3062. doi: 10.1161/STROKEAHA.107.488536.
54. Tilley BC, Marler J, Geller NL, Lu M, Legler J, Brott T, Lyden P, Grotta J. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke. 1996;27:2136-2142.
55. Howard G, Waller JL, Voeks JH, Howard VJ, Jauch EC, Lees KR, Nichols FT, Rahlfs VW, Hess DC. A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes. Stroke. 2012;43:664-669. doi: 10.1161/STROKEAHA.111.632935.
56. Sajobi TT, Zhang Y, Menon BK, Goyal M, Demchuk AM, Broderick JP, Hill MD. Effect size estimates for the ESCAPE Trial: proportional odds regression versus other statistical methods. Stroke. 2015;46:1800-1805. doi: 10.1161/STROKEAHA.115.009328.
57. Elvidge AR, Werner A. Hemiplegia and thrombosis of the internal carotid system. AMA Arch Neurol Psychiatry. 1951;66:752-782.
58. Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J Am Med Assoc. 1958;167:1705-1709.
59. Denny-Brown D, Meyer JS. The cerebral collateral circulation. II. Production of cerebral infarction by ischemic anoxia and its reversibility in early stages. Neurology. 1957;7:567-579.
60. Howell DA, Tatlow WF, Feldman S. Observations on anticoagulant therapy in thromboembolic disease of the brain. Can Med Assoc J. 1964;90:611-614.
61. Fletcher AP, Alkjaersig N, Lewis M, Tulevski V, Davies A, Brooks JE, Hardin WB, Landau WM, Raichle ME. A pilot study of urokinase therapy in cerebral infarction. Stroke. 1976;7:135-142.
62. JOHNSON AJ, McCARTY WR. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest. 1959;38:1627-1643. doi: 10.1172/JCI103941.
63. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology. 1963;13:927-937.
64. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Anticoagulants plus streptokinase therapy in progressive stroke. JAMA. 1964;189:373.
65. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. New Engl I Med. 1996;335:145-150.
66. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA. 1996;276:961-966.
67. Ciccone A, Motto C, Aritzu E, Piana A, Candelise L. Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis. MAST-I Collaborative Group. Multicentre Acute Stroke Trial-Italy. Lancet. 1998;352:880.
68. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. New Engl J Med. 1985;312:932-936.
69. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 1985;230:1289-1292.
70. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86. doi: 10.1002/ana.410320113.
71. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
72. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23:641-645.
73. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med. 1995;333:1581-1587.
74. Casaubon LK, Boulanger JM, Blacquiere D, et al; Heart and Stroke Foundation of Canada Canadian Stroke Best Practices Advisory Committee. Canadian Stroke Best Practice Recommendations: Hyperacute Stroke Care Guidelines, Update 2015. Int J Stroke. 2015;10:924-940. doi: 10.1111/ijs.12551.
75. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947. doi: 10.1161/STR.0b013e318284056a.
76. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
77. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
78. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-2026.
79. Hacke W, Donnan G, Fieschi C, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774. doi: 10.1016/S0140-6736(04)15692-4.
80. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
81. Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, Wardlaw J, Hacke W. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8:1095-1102. doi: 10.1016/S1474-4422(09)70264-9.
82. Davis SM, Donnan GA, Parsons MW, et al; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309. doi: 10.1016/S1474-4422(08)70044-9.
83. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352-2363.
84. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703. doi: 10.1016/S0140-6736(10)60491-6.
85. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, Cohen G. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379:2364-2372. doi: 10.1016/S0140-6736(12)60738-7.
86. Campbell BC, Christensen S, Parsons MW, et al; EPITHET and DEFUSE Investigators. Advanced imaging improves prediction of hemorrhage after stroke thrombolysis. Ann Neurol. 2013;73:510-519. doi: 10.1002/ana.23837.
87. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Levine SR; mMulticentre tPA Stroke Survey Group. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57:474-480.
88. Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD; Canadian Alteplase for Stroke Effectiveness Study Investigators. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care. 2009;32:617-622. doi: 10.2337/dc08-1754.
89. Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol. 1996;78:2-7.
90. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73. doi: 10.1161/01. STR.0000149938.08731.2c.
91. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231. doi: 10.1161/01.STR.0000217403.66996.6d.
92. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141-150. doi: 10.1016/S1474-4422(08)70267-9.
93. Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Grønning BA, Chabriat H, Chang KC, Davalos AE, Ford GA, Grotta J, Kaste M, Schwamm LH, Shuaib A; DIAS-3 Investigators. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015;14:575-584. doi: 10.1016/S1474-4422(15)00047-2.
94. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41:707-711. doi: 10.1161/STROKEAHA.109.572040.
95. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099-1107. doi: 10.1056/NEJMoa1109842.
96. Docagne F, Parcq J, Lijnen R, Ali C, Vivien D. Understanding the functions of endogenous and exogenous tissue-type plasminogen activator during stroke. Stroke. 2015;46:314-320. doi: 10.1161/STROKEAHA.114.006698.
97. Coutts SB, Dubuc V, Mandzia J, et al; TEMPO-1 Investigators. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015;46:769-774. doi: 10.1161/STROKEAHA.114.008504.
98. Yu AY, Hill MD, Coutts SB. Should minor stroke patients be thrombolyzed? A focused review and future directions. Int J Stroke. 2015;10:292-297. doi: 10.1111/ijs.12426.
99. Zeumer H, Hündgen R, Ferbert A, Ringelstein EB. Local intraarterial fibrinolytic therapy in inaccessible internal carotid occlusion. Neuroradiology. 1984;26:315-317.
100. del Zoppo GJ, Ferbert A, Otis S, Brückmann H, Hacke W, Zyroff J, Harker LA, Zeumer H. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke. 1988;19:307-313.
101. Hacke W, Zeumer H, Ferbert A, Brückmann H, del Zoppo GJ. Intraarterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke. 1988;19:1216-1222.
102. Zeumer H, Freitag HJ, Zanella F, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology. 1993;35:159-162.
103. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4-11.
104. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
105. Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T; MELT Japan Study Group. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke. 2007;38:2633-2639. doi: 10.1161/STROKEAHA.107.488551.
106. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598-2605.
107. The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004;35:904-911.
108. IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007;38:2127-2135.
109. Ciccone A, Valvassori L, Ponzio M, Ballabio E, Gasparotti R, Sessa M, Scomazzoni F, Tiraboschi P, Sterzi R; SYNTHESIS Investigators. Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neurointerv Surg. 2010;2:74-79. doi: 10.1136/jnis.2009.001388.
110. Mazighi M, Serfaty JM, Labreuche J, et al; RECANALISE investigators. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol. 2009;8:802-809. doi: 10.1016/S1474-4422(09)70182-6.
111. Ciccone A, Valvassori L; SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368:2433-2434.
112. Kidwell CS, Jahan R, Alger JR, Schaewe TJ, Guzy J, Starkman S, Elashoff R, Gornbein J, Nenov V, Saver JL; MR RESCUE Investigators. Design and rationale of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) Trial. Int J Stroke. 2014;9:110-116. doi: 10.1111/j.1747-4949.2012.00894.x.
113. Kidwell CS, Jahan R, Gornbein J, et al MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368:914-923. doi: 10.1056/NEJMoa1212793.
114. Broderick JP, Palesch YY, Demchuk AM, et al; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368:893-903. doi: 10.1056/NEJMoa1214300.
115. Goyal M, Almekhlafi MA, Fan L, Menon BK, Demchuk AM, Yeatts SD, Hill MD, Tomsick T, Khatri P, Zaidat OO, Jauch EC, Eesa M, Jovin TG, Broderick JP. Evaluation of interval times from onset to reperfusion in patients undergoing endovascular therapy in the Interventional Management of Stroke III trial. Circulation. 2014;130:265-272. doi: 10.1161/CIRCULATIONAHA.113.007826.
116. Demchuk AM, Goyal M, Yeatts SD, et al; IMS III Investigators. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology. 2014;273:202-210. doi: 10.1148/radiol.14132649.
117. Balasubramaian A, Mitchell P, Dowling R, Yan B. Evolution of endovascular therapy in acute stroke: implications of device development. J Stroke. 2015;17:127-137. doi: 10.5853/jos.2015.17.2.127.
118. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, Johnston KC, Johnston SC, Khalessi AA, Kidwell CS, Meschia JF, Ovbiagele B, Yavagal DR; American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46:3020-3035. doi: 10.1161/STR.0000000000000074.
119. Ding D. Endovascular mechanical thrombectomy for acute ischemic stroke: a new standard of care. J Stroke. 2015;17:123-126. doi: 10.5853/jos.2015.17.2.123.
120. Almekhlafi MA, Menon BK, Goyal M. Lessons learnt from recent endovascular stroke trials: finding a way to move forward. Expert Rev Cardiovasc Ther. 2014;12:429-436. doi: 10.1586/14779072.2014.894885.
121. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, Hardemark HG, Rodichok L; SAINT I and II Investigators. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39:1751-1758. doi: 10.1161/STROKEAHA.107.503334.
122. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, Waldman BD, Tamariz D, Ryckborst KJ; ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. 2013;12:1049-1058. doi: 10.1016/S1474-4422(13)70223-0.
123. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke. 1995;26:254-258.
124. Davis SM, Albers GW, Diener HC, Lees KR, Norris J. Termination of acute stroke studies involving selfotel treatment. ASSIST steering committed. Lancet. 1997;349:32.
125. Sacco RL, DeRosa JT, Haley EC Jr, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JL; Glycine Antagonist in Neuroprotection Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA. 2001;285:1719-1728.
126. Hill MD, Martin RH, Mikulis D, et al; ENACT trial investigators. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11:942-950. doi: 10.1016/S1474-4422(12)70225-9.
127. Ntaios G, Dziedzic T, Michel P, Papavasileiou V, Petersson J, Staykov D, Thomas B, Steiner T; European Stroke Organisation. European Stroke Organisation (SEE) guidelines for the management of temperature in patients with acute ischemic stroke. Int J Stroke. 2015;10:941-949. doi: 10.1111/ijs.12579.
128. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2007;6:1063-1072. doi: 10.1016/S1474-4422(07)70274-0.
129. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ (Clinical research ed). 2004;328:326.
130. Patarroyo SX, Anderson C. Blood pressure lowering in acute phase of stroke: latest evidence and clinical implications. Ther Adv Chronic Dis. 2012;3:163-171. doi: 10.1177/2040622312450183.
131. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
132. Li X, Zhou G, Zhou X, Zhou S. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. J Neurol Sci. 2013;332:92-96. doi: 10.1016/j.jns.2013.06.025.
133. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6:961-969. doi: 10.1016/S1474-4422(07)70250-8.
134. Skliut M, Jamieson DG. Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT. Curd Cardiol Rep. 2008;10:9-16.
135. Huang DY, Eisert WG. CHANCE trial: early short-term dual antiplatelet treatment for stroke prevention. Stroke. 2013;44:3623-3624. doi: 10.1161/STROKEAHA.113.003380.
136. Johnston SC, Easton JD, Farrant M, Barsan W, Battenhouse H, Conwit R, Dillon C, Elm J, Lindblad A, Morgenstern L, Poisson SN, Palesch Y. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013;8:479-483. doi: 10.1111/ijs.12129.
137. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Held P, Jonasson J, Minematsu K, Molina CA, Wong LK. Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design. Int J Stroke. 2015;10:1304-1308. doi: 10.1111/ijs.12610.
138. Krishnan K, Beridze M, Christensen H, Dineen R, Duley L, Heptinstall S, James M, Markus HS, Pocock S, Ranta A, Robinson T, Nikola N, Venables G, Bath P. Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388). Int I Stroke. 2015;10:1159-1165.
139. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke. 2008;39:2396-2399. doi: 10.1161/STROKEAHA.107.505776.
140. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305-1316. doi: 10.1056/NEJMoa043033.
141. Derdeyn CP, Chimowitz MI, Lynn MJ, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014;383:333-341. doi: 10.1016/S0140-6736(13)62038-3.
142. Liu L, Wong KS, Leng X, Pu Y, Wang Y, Jing J, Zou X, Pan Y, Wang A, Meng X, Wang C, Zhao X, Soo Y, Johnston SC, Wang Y; CHANCE Investigators. Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE. Neurology. 2015;85:1154-1162. doi: 10.1212/WNL.0000000000001972.
143. Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: The RAF Study. Stroke. 2015;46:2175-2182. doi: 10.1161/STROKEAHA.115.008891.
144. Zhang J, Xu RW, Fan X, Ye Z, Liu P. A systematic review of early results following synchronous or staged carotid artery stenting and coronary artery bypass grafting. Thorac Cardiovasc Surg. 2015.
145. Mantese VA, Timaran CH, Chiu D, Begg RJ, Brott TG; CREST Investigators. The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): stenting versus carotid endarterectomy for carotid disease. Stroke. 2010;41:S31-S34. doi: 10.1161/STROKEAHA.110.595330.
146. Brott TG, Howard G, Roubin GS, et al; CREST Investigators. Longterm results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med. 2016;374:1021-1031. doi: 10.1056/NEJMoa1505215.
147. North American Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New Engl J Med. 1991;325:445-453.
148. Bazan HA, Zea N, Jennings B, Smith TA, Vidal G, Sternbergh WC III. Urgent carotid intervention is safe after thrombolysis for minor to moderate acute ischemic stroke. J Vasc Surg. 2015;62:1529-1538. doi: 10.1016/j.jvs.2015.07.082.
149. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ; Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363:915-924. doi: 10.1016/S0140-6736(04)15785-1.
150. Wang Y, Johnston SC, Wang Y. Clopidogrel with aspirin in minor stroke or transient ischemic attack. N Engl J Med. 2013;369:1376-1377. doi: 10.1056/NEJMc1309713.
151. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New Engl J Med. 2012;367:817-825.
152. Molina CA, Alvarez-Sabín J, Schonewille W, Montaner J, Rovira A, Abilleira S, Codina A. Cerebral microembolism in acute spontaneous internal carotid artery dissection. Neurology. 2000;55:1738-1740.
153. Markus HS, Hayter E, Levi C, Feldman A, Venables G, Norris J. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. The Lancet Neurology. 2015;14:361-367.
154. Higgins JR, de Swiet M. Blood-pressure measurement and classification in pregnancy. Lancet. 2001;357:131-135. doi: 10.1016/S0140-6736(00)03552-2.